Open-Label Extension Study to Investigate the Continued Safety and Effect of ONO 2506PO (1200 mg OD).
Latest Information Update: 13 Apr 2022
At a glance
- Drugs Arundic acid (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Sponsors Ono Pharmaceutical
Most Recent Events
- 13 Apr 2022 New trial record